Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 13/20 | 0.59 |
| ▸ | HTR1A | P08908 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 8/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009358 | 0.89 | JAK1 (0.58) | JAK1HTR1ASLC6A4ADRA1DADRA1A | |
| SCHEMBL27819451 | 0.80 | HTR1A (0.46) | JAK1HTR1ASLC6A4ADRA1DADRA1A | |
| SCHEMBL18852707 | 0.78 | CDK9 (0.46) | JAK1HTR1ASLC6A4ADRA1DADRA1A | |
| SCHEMBL14493885 | 0.78 | JAK1 (0.57) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL30356127 | 0.75 | JAK1 (1.00) | JAK1 | |
| SCHEMBL20923480 | 0.75 | JAK1 (1.00) | JAK1 | |
| SCHEMBL30009608 | 0.73 | JAK1 (0.59) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL14493878 | 0.71 | CCNT1 (0.50) | JAK1JAK3AURKB | |
| SCHEMBL30009237 | 0.70 | JAK1 (0.52) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL30009512 | 0.70 | AURKB (0.50) | JAK1JAK2JAK3AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885HTR1A 4172/4885SLC6A4 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.